Skip to main content
OpenTrials
Completed

NCT Number: NCT01798420

Corticosteroids and Hemoglobin A1C Levels in Diabetic Patients With COPD Exacerbation

Corticosteroid treatment in diabetic patients admitted for COPD exacerbation are expected to significantly increase hemoglobin A1C levels

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Chronic Disease Chronic Obstructive Pulmonary Disease Diabetes Mellitus Disease Attributes Endocrine System Diseases Glucose Metabolism Disorders Lung Diseases Lung Diseases, Obstructive Metabolic Diseases Nutritional and Metabolic Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of medicine

Nzareth, Nazareth, 16000, Israel

About this study

HbA1C levels were evaluated in diabetic patients with COPD exacerbation on admission to the hospital and 3-months later. Demographic, clinical, laboratory variables and total steroid dose were documented. Age- and sex-matched group of diabetic patients with COPD who were admitted for other reasons, were asked to participate as a control group. Mann-Whitney and Chi square/Fischer's exact tests were used to compare between the parameters of the two groups. Wilcoxon signed rank test was used to compare between HbA1C levels at baseline and 3 months later. Multi-variate linear regression analysis was used to find predictors for increase in HbA1C levels in the patients' group.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diabetic patients with COPD exacerbation

Exclusion criteria

  • Patients treated with steroids during the previous 3 months

Treatment and study plan

Primary outcomes

  1. Hemoglobin A1C LEVEL

    Time frame: 3 MONTHS

Secondary outcomes

  1. Glucose levels

    Time frame: 3 months

Other outcomes

  1. Weight

    Time frame: 3 months

Sponsors and collaborators

Lead sponsor

The Nazareth Hospital, Israel

Other

Registry information

Official study title

The Impact of Corticosteroid Treatment on Hemoglobin A1C Levels in Diabetic Patients With COPD Exacerbation

Important dates

Study start
2012
Primary completion
2012
Study completion
2012
First posted
Feb 25, 2013
Registry last updated
Feb 25, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.